$CODX
Co-Diagnostics, Inc. Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027538 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$2.457M	$197.8K
YoY Change	-51.77%	-96.06%
Cost Of Revenue	$255.8K	$459.1K
YoY Change	-66.69%	-49.85%
Gross Profit	$2.201M	-$261.3K
YoY Change	-49.12%	-106.36%
Gross Profit Margin	89.59%	-132.09%
Selling, General & Admin	$5.052M	$5.447M
YoY Change	-8.35%	38.22%
% of Gross Profit	229.5%
Research & Development	$5.789M	$5.981M
YoY Change	14.91%	53.76%
% of Gross Profit	262.97%
Depreciation & Amortization	$300.0K	$305.3K
YoY Change	-4.15%	-27.98%
% of Gross Profit	13.63%
Operating Expenses	$11.14M	$11.73M
YoY Change	2.53%	42.14%
Operating Profit	-$8.936M	-$11.99M
YoY Change	36.73%	189.23%
Interest Expense	$700.0K	$477.9K
YoY Change	313.86%	-1165.53%
% of Operating Profit
Other Income/Expense, Net	$840.2K	$837.3K
YoY Change	-72.54%	16.42%
Pretax Income	-$8.096M	-$11.16M
YoY Change	132.93%	225.49%
Income Tax	-$2.114M	-$2.238M
% Of Pretax Income
Net Earnings	-$5.982M	-$8.919M
YoY Change	339.52%	232.01%
Net Earnings / Revenue	-243.47%	-4508.87%
Basic Earnings Per Share	-$0.20	-$0.31
Diluted Earnings Per Share	-$0.20	-$0.31
COMMON SHARES
Basic Shares Outstanding	30.79M shares	30.26M shares
Diluted Shares Outstanding	29.36M shares	29.09M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.43M	$69.14M
YoY Change	-26.66%	-27.98%
Cash & Equivalents	$10.24M	$13.83M
Short-Term Investments	$53.19M	$55.31M
Other Short-Term Assets	$1.300M	$982.0K
YoY Change	-1.23%	-38.8%
Inventory	$4.520M	$4.691M
Prepaid Expenses
Receivables	$806.7K	$1.097M
Other Receivables	$1.300M	$1.477M
Total Short-Term Assets	$71.31M	$77.39M
YoY Change	-30.03%	-32.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.808M	$2.795M
YoY Change	15.18%	15.43%
Goodwill
YoY Change
Intangibles	$26.48M	$26.56M
YoY Change	-1.47%	-1.58%
Long-Term Investments	$800.0K	$824.8K
YoY Change	6.85%	-5.96%
Other Assets	$4.300M	$2.012M
YoY Change
Total Long-Term Assets	$37.37M	$35.42M
YoY Change	-18.63%	-23.46%
TOTAL ASSETS
Total Short-Term Assets	$71.31M	$77.39M
Total Long-Term Assets	$37.37M	$35.42M
Total Assets	$108.7M	$112.8M
YoY Change	-26.49%	-29.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.416M	$1.712M
YoY Change	-31.1%	101.82%
Accrued Expenses	$1.827M	$1.629M
YoY Change	20.83%	-10.45%
Deferred Revenue	$349.5K	$258.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.098M	$5.116M
YoY Change	-15.21%	-23.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.100M	$4.253M
YoY Change	32.84%	-2.08%
Total Long-Term Liabilities	$4.094M	$4.253M
YoY Change	-40.52%	-55.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.098M	$5.116M
Total Long-Term Liabilities	$4.094M	$4.253M
Total Liabilities	$9.192M	$9.369M
YoY Change	-28.72%	-42.77%
SHAREHOLDERS EQUITY
Retained Earnings	$19.27M	$25.26M
YoY Change	-68.83%	-60.04%
Common Stock	$35.37K	$35.35K
YoY Change	3.01%	3.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$15.42M	$15.25M
YoY Change	18.64%	486.65%
Treasury Stock Shares
Shareholders Equity	$99.49M	$103.4M
YoY Change
Total Liabilities & Shareholders Equity	$108.7M	$112.8M
YoY Change	-26.49%	-29.87%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$5.982M	-$8.919M
YoY Change	339.52%	232.01%
Depreciation, Depletion And Amortization	$300.0K	$305.3K
YoY Change	-4.15%	-27.98%
Cash From Operating Activities	-$6.590M	-$5.209M
YoY Change	-689.28%	-414.88%
INVESTING ACTIVITIES
Capital Expenditures	$240.0K	$484.2K
YoY Change	-204.33%	-195.4%
Acquisitions
YoY Change
Other Investing Activities	$3.400M	$13.72M
YoY Change	-31.58%	-237.88%
Cash From Investing Activities	$3.170M	$13.24M
YoY Change	-33.11%	-226.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-160.0K	-555.7K
YoY Change	-98.46%	-78.39%
NET CHANGE
Cash From Operating Activities	-6.590M	-5.209M
Cash From Investing Activities	3.170M	13.24M
Cash From Financing Activities	-160.0K	-555.7K
Net Change In Cash	-3.580M	7.471M
YoY Change	-21.1%	-165.68%
FREE CASH FLOW
Cash From Operating Activities	-$6.590M	-$5.209M
Capital Expenditures	$240.0K	$484.2K
Free Cash Flow	-$6.830M	-$5.694M
YoY Change	-606.54%	-363.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax		usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38148
	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite D
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
	dei	City Area Code CityAreaCode	(801)
	dei	Local Phone Number LocalPhoneNumber	438-1036
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CODX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30788871	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13830846	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	55307146	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58289066	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1097393	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4691068	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2023Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	1439451	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1870419	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	981996	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	761187	usd
CY2023Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	37500	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	77385400	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92733671	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2795023	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2012181	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3228774	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	372115	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26555000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q2	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	824808	usd
CY2022Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	672679	usd
CY2023Q2	us-gaap	Assets Assets	112801186	usd
CY2022Q4	us-gaap	Assets Assets	123086281	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1712204	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	952296	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1628765	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	772515	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297209	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	744172	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112801186	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123086281	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	197806	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5023226	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	799763	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1689471	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	257999	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5115655	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3873423	usd
CY2023Q2	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1203975	usd
CY2022Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1181284	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2417987	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2458072	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50708	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	591107	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	1042885	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4253154	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4692864	usd
CY2023Q2	us-gaap	Liabilities Liabilities	9368809	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8566287	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35348350	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30788871	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34754265	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30872607	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	35348	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	34754	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4559479	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	15249796	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	14211866	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92810883	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88472935	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	579127	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25256815	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	39931031	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103432377	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27722270	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	459095	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	915432	usd
	us-gaap	Cost Of Revenue CostOfRevenue	961336	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4197383	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	-261289	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	4107794	usd
	us-gaap	Gross Profit GrossProfit	-161573	usd
	us-gaap	Gross Profit GrossProfit	23524887	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1732966	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1472225	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3439297	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4124373	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3713895	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2468421	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6727860	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5390616	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5981043	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3889844	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10995103	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7661171	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	305246	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	424342	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	621256	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	671606	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	11733150	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8254832	usd
	us-gaap	Operating Expenses OperatingExpenses	21783516	usd
	us-gaap	Operating Expenses OperatingExpenses	17847766	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11994439	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4147038	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21945089	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	5677121	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	191892	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	61671	usd
	us-gaap	Interest Income Other InterestIncomeOther	394264	usd
	us-gaap	Interest Income Other InterestIncomeOther	73064	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	411190	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	829272	usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-48740	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-142161	usd
CY2023Q2	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	359405	usd
CY2022Q2	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	812822	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1397077	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	4192712	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-125193	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-106525	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	152129	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-127864	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	837294	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	4192712	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	26012	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	719228	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2772742	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3995751	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11157145	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3427810	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19172347	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9672872	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2238320	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-741507	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4498131	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	644580	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8918825	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14674216	usd
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	107366	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	285987	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	107366	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	285987	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8811459	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2686303	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14388229	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9028292	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29088159	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32472251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29284175	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32509664	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29088159	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32472251	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29284175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33253612	shares
	us-gaap	Net Income Loss NetIncomeLoss	-14674216	usd
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	621256	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	671606	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4338542	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2908381	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1397077	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	13761	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	152129	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-127864	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-142161	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4430168	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1917871	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	314626	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11404	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2041704	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8567769	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-247659	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-791453	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-620078	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2920658	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	257999	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22691	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1918510	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1454226	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1702718	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10708797	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9460222	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	664137	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	904160	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	69393987	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1255266	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	66126080	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9951550	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2603770	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9600444	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	177871	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1037930	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2599478	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1037930	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2421607	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9142957	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2561829	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22973803	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13830846	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86045405	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	49197	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4534330	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	673	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3063782	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	681728	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2168742	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	482196	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	178621	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5755391	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	110629770	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	110629770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2169800	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	555734	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	107366	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8918825	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8918825	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103432377	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103432377	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475100	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475100	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50001	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1375097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11714595	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	147714793	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	147714793	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27869	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1533284	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2599478	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470941	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470941	usd
	CODX	Reclassifications Policytext Block ReclassificationsPolicytextBlock	<p id="xdx_848_ecustom--ReclassificationsPolicytextBlock_zL4M4rMeREze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zm5dMb98dXaj">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	58289066	usd
CY2023Q2	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	68369170	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4510545	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3413152	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1097393	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6552249	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3098526	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	768822	usd
CY2023Q2	us-gaap	Trading Securities TradingSecurities	69137992	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13830846	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	55307146	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4691068	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	842087	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3848981	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1327264	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3983209	usd
CY2022Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	80873628	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	389241	usd
CY2022Q4	us-gaap	Trading Securities TradingSecurities	81262869	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5981043	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10995103	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3889844	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7661171	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zc8XDXM29Fff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zu4k1LGRB7H3">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zXnpGEoeRBXh" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zdMH8peZNNsi" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the three and six months ended June 30, 2023. Three customers accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zG4goerzTycc" title="Concentration risk percentage">44</span>% of total revenue for the three months ended June 30, 2023, and two customers accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGlt6JDi0vz3" title="Concentration risk percentage">33</span>% of total revenue for the six months ended June 30, 2023. One customer accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zATriS7edAF5" title="Concentration risk percentage">55</span>% of total revenue for the three months ended June 30, 2022, and two customers accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLKl246dQafc" title="Concentration risk percentage">46</span>% of total revenue for the six months ended June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three customers accounted for more than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zuyGu8dYn5T6" title="Concentration risk percentage">10</span>% of accounts receivable at June 30, 2023 and one customer accounted for more than <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zEvZpvv60nrl" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2022. These customers together accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zhtdrb8mguCe" title="Concentration risk percentage">77</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5B8DkuQPUA3" title="Concentration risk percentage">37</span>% of accounts receivable at June 30, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-640000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26555000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-426667	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	151332	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	302668	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	454000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2732356	usd
	CODX	Contingent Considered Issued For Business Acquisitions ContingentConsideredIssuedForBusinessAcquisitions	-1397077	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1335279	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y6M
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	197806	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5023226	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	799763	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27722270	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	197806	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5023226	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	799763	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27722270	usd
	CODX	Increase Due To Prepayments From Customers IncreaseDueToPrepaymentsFromCustomers	18120	usd
	CODX	Increase Due To Prepayments From Grants Received IncreaseDueToPrepaymentsFromGrantsReceived	239879	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	257999	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8918825	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14674216	usd
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29088159	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32472251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29284175	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32509664	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	743948	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29088159	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32472251	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29284175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33253612	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1391156	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1155136	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M17D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y4M20D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2023Q2	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.81
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	2.43
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2023Q2	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2023Q2	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	1.11
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P3Y6M
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2169800	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1533286	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4338542	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2908381	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2238320	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.201	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4498131	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.235	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-741507	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	644580	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	62847	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	150454	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	48301	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	156979	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	111148	usd
	us-gaap	Lease Cost LeaseCost	307433	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	467651	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	966451	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	987252	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	682806	usd
CY2023Q2	CODX	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	542512	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3646672	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	416085	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3230587	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	772515	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2458072	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	281421	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062	pure
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	677821	shares
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4559479	shares

Files In Submission

Name	View Source	Status
0001493152-23-027538-index-headers.html	Edgar Link	pending
0001493152-23-027538-index.html	Edgar Link	pending
0001493152-23-027538.txt	Edgar Link	pending
0001493152-23-027538-xbrl.zip	Edgar Link	pending
codx-20230630.xsd	Edgar Link	pending
codx-20230630_def.xml	Edgar Link	unprocessable
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
codx-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
codx-20230630_cal.xml	Edgar Link	unprocessable
codx-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics, Inc. Stock $codx

2023 Q3 Form 10-Q Financial Statement

#000149315223027538 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics, Inc. Stock $codx

2023 Q3 Form 10-Q Financial Statement

#000149315223027538 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics, Inc. Stock $codx